SG Americas Securities LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX)

SG Americas Securities LLC acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,597 shares of the company’s stock, valued at approximately $93,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NKTX. RA Capital Management L.P. lifted its holdings in shares of Nkarta by 38.4% in the 1st quarter. RA Capital Management L.P. now owns 10,805,129 shares of the company’s stock valued at $116,803,000 after acquiring an additional 3,000,000 shares during the last quarter. SR One Capital Management LP raised its position in Nkarta by 150.0% during the first quarter. SR One Capital Management LP now owns 3,333,333 shares of the company’s stock valued at $36,033,000 after purchasing an additional 2,000,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Nkarta by 26.0% in the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock valued at $21,255,000 after purchasing an additional 405,753 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Nkarta by 12.0% in the 2nd quarter. Renaissance Technologies LLC now owns 912,872 shares of the company’s stock worth $5,395,000 after purchasing an additional 98,000 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of Nkarta in the 1st quarter worth approximately $9,072,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NKTX. HC Wainwright lowered their price target on Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Needham & Company LLC restated a “buy” rating and issued a $13.00 target price on shares of Nkarta in a report on Wednesday, August 14th. Raymond James raised shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price objective on the stock in a research report on Wednesday, August 14th. Rodman & Renshaw began coverage on shares of Nkarta in a research note on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.50.

Nkarta Price Performance

Shares of NKTX opened at $3.46 on Tuesday. The firm has a market capitalization of $244.14 million, a price-to-earnings ratio of -1.72 and a beta of 0.80. Nkarta, Inc. has a 1-year low of $1.86 and a 1-year high of $16.24. The company has a 50-day moving average of $4.77 and a 200 day moving average of $5.82.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.15. On average, equities analysts anticipate that Nkarta, Inc. will post -1.92 earnings per share for the current fiscal year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.